Literature DB >> 28422790

Particle-based delivery of the HIV envelope protein.

Benedikt Asbach1, Ralf Wagner.   

Abstract

PURPOSE OF REVIEW: A major focus in HIV vaccine research is the development of suitable antigens that elicit broadly neutralizing antibody responses targeting HIV's envelope protein (Env). Delivery of Env in a repetitive manner on particle-based carriers allows higher avidity interactions and is therefore expected to efficiently engage B cells, thus leading to affinity maturation that results in superior antibody responses characterized by improved breadth, potency, and durability. This review summarizes current work that is evaluating diverse types of such particulate carriers for Env delivery. RECENT
FINDINGS: Various types of particle scaffolds are being investigated, encompassing group-specific antigen-derived virus-like particles, bacteria-derived proteins that self-assemble into symmetrical nanoparticles, as well as liposomes assembled from membrane components and recombinantly produced Env isoforms. Env-derived antigens from peptides over selected isolates to improved, stabilized next-generation designer Envs have been attached to such carriers. Immunological evaluation in animal models showed that these structures often elicit superior humoral immune responses.
SUMMARY: The findings reviewed here emphasize the potential of particle-based delivery modalities to elicit better antibody responses. Together with advances in Env antigen design, these approaches may synergistically act together on the way to obtain vaccine candidates that potentially induce protective immune responses against HIV.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28422790     DOI: 10.1097/COH.0000000000000366

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  8 in total

Review 1.  Mass spectrometry for the identification and analysis of highly complex glycosylation of therapeutic or pathogenic proteins.

Authors:  Yukako Ohyama; Kazuki Nakajima; Matthew B Renfrow; Jan Novak; Kazuo Takahashi
Journal:  Expert Rev Proteomics       Date:  2020-05-28       Impact factor: 3.940

Review 2.  Strategies for eliciting multiple lineages of broadly neutralizing antibodies to HIV by vaccination.

Authors:  Zekun Mu; Barton F Haynes; Derek W Cain
Journal:  Curr Opin Virol       Date:  2021-11-04       Impact factor: 7.121

Review 3.  Glycosylation in health and disease.

Authors:  Colin Reily; Tyler J Stewart; Matthew B Renfrow; Jan Novak
Journal:  Nat Rev Nephrol       Date:  2019-06       Impact factor: 42.439

4.  Induction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus Vector.

Authors:  C Anika Bresk; Tamara Hofer; Sarah Wilmschen; Marina Krismer; Anja Beierfuß; Grégory Effantin; Winfried Weissenhorn; Michael J Hogan; Andrea P O Jordan; Rebecca S Gelman; David C Montefiori; Hua-Xin Liao; Joern E Schmitz; Barton F Haynes; Dorothee von Laer; Janine Kimpel
Journal:  Viruses       Date:  2019-02-15       Impact factor: 5.048

5.  Neutralizing Antibody Induction by HIV-1 Envelope Glycoprotein SOSIP Trimers on Iron Oxide Nanoparticles May Be Impaired by Mannose Binding Lectin.

Authors:  Rajesh P Ringe; Victor M Cruz Portillo; Pia Dosenovic; Thomas J Ketas; Gabriel Ozorowski; Bartek Nogal; Lautaro Perez; Celia C LaBranche; Jillian Lim; Erik Francomano; Ian A Wilson; Rogier W Sanders; Andrew B Ward; David C Montefiori; Michel C Nussenzweig; P J Klasse; Albert Cupo; John P Moore
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

6.  Augmenting the Immune Response against a Stabilized HIV-1 Clade C Envelope Trimer by Silica Nanoparticle Delivery.

Authors:  David Peterhoff; Stefanie Thalhauser; Jan M Sobczak; Mona O Mohsen; Christoph Voigt; Nicole Seifert; Patrick Neckermann; Alexandra Hauser; Song Ding; Quentin Sattentau; Martin F Bachmann; Miriam Breunig; Ralf Wagner
Journal:  Vaccines (Basel)       Date:  2021-06-11

Review 7.  Virus-Like Particle, Liposome, and Polymeric Particle-Based Vaccines against HIV-1.

Authors:  Yong Gao; Chanuka Wijewardhana; Jamie F S Mann
Journal:  Front Immunol       Date:  2018-02-28       Impact factor: 7.561

8.  Advantages and Limitations of Integrated Flagellin Adjuvants for HIV-Based Nanoparticle B-Cell Vaccines.

Authors:  Cornelia Barnowski; Nicole Kadzioch; Dominik Damm; Huimin Yan; Vladimir Temchura
Journal:  Pharmaceutics       Date:  2019-05-01       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.